Biological Phosphocalcic Metabolism and Coronary Artery Calcifications

Completed

• Conditions: Cardiovascular Disease
• Interventions: Other: 24 h urines analyses

• Registration Number: NCT02792868
• Lead Sponsor: French Cardiology Society

Brief Summary

Study a sample of patients in primary prevention, moderate cardiovascular risk (n = 83 patients), with normal, non-diabetic renal function. The investigators quantify the phophocalcic intake and excretion, realizing a food examination and a urine collection of 24 particular. The investigators will measure plasma levels of FGF23 serum calcium, phosphatemia, the investigators will calculate the tubular reabsorption of phosphate. The investigators will conduct a quantitative assessment of coronary calcification by a non-injected CT scan, measuring semi automated way Agatston calcium score. There will be an analysis of collinearity. An adjustment will be made for confounding variables in a generalized linear regression model.

Detailed Description

Not available

Study Timeline

• Study Start: 2016-04
• Study First Submitted: 2016-05-26
• Study First Submitted QC: 2016-06-02
• Study First Posted: 2016-06-08
• Primary Completion: 2017-03
• Study Completion: 2017-03
• Status Verified: 2017-04
• Last Update Submitted: 2017-04-06
• Last Update Posted: 2017-04-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 83

Inclusion Criteria

• Hospitalization for a cardiovascular check in the Detection Centre and the Atherosclerosis Prevention (CHU Rangueil Toulouse)
• In primary prevention of coronary heart disease
• Introducing an intermediate cardiovascular risk according to the European SCORE equation, that is to say, a risk of cardiovascular death at 10 years greater than or equal to 1% and less than 5%
• signed the informed consent,

Exclusion Criteria

• Chronic renal failure patients with an estimated GFR less than 60 mL / min / 1.73m2, due to alterations in phosphate metabolism,
• Patients receiving glucose-lowering therapy,
• Patients with a fasting blood glucose greater capillary or equal to 1.10 g / l, confirmed by a plasma glucose greater than or equal to 1.10g / l.
• The diuretic therapy patients (due to a change in urinary electrolytes)
• HIV-positive patients for HIV, antiretroviral (due to a change in urinary electrolytes)
• Pregnant women,
• Patients under judicial protection, guardianship or trusteeship.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
patient	24 h urines analyses	patient with cardiovascular risk (moderate)

Primary Outcome Measures

Name	Time	Method
plasma levels of FGF23 according to the calcium score, determined by an ELISA method	1 day

Trial Locations

Locations (1)

Chu Rangueil; 🇫🇷 Toulouse, France